Market closedNon-fractional
InMode/INMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About InMode
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Ticker
INMD
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Yokne'am, Israel
Employees
581
Website
www.inmodemd.com
InMode Metrics
BasicAdvanced
$1.5B
Market cap
8.34
P/E ratio
$2.11
EPS
2.16
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
2.16
Financial strength
Current ratio
13.45
Quick ratio
12.365
Long term debt to equity
0.762
Total debt to equity
0.762
Management effectiveness
Return on assets (TTM)
13.83%
Return on equity (TTM)
25.54%
Valuation
Price to earnings (TTM)
8.343
Price to revenue (TTM)
3.166
Price to book
1.82
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
8.231
Growth
Revenue change (TTM)
-1.72%
Earnings per share change (TTM)
5.45%
3-year revenue growth (CAGR)
26.34%
3-year earnings per share growth (CAGR)
23.19%
What the Analysts think about InMode
Analyst Ratings
Majority rating from 6 analysts.
InMode Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$80M
-36.70%
Net income
$24M
-57.17%
Profit margin
29.42%
-32.34%
InMode Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.72
$0.61
$0.71
$0.32
-
Expected
$0.64
$0.64
$0.67
$0.41
$0.49
Surprise
11.92%
-4.74%
6.23%
-21.47%
-
InMode News
AllArticlesVideos
DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer
PRNewsWire·2 days ago
Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
PRNewsWire·1 week ago
InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for InMode stock?
InMode (INMD) has a market cap of $1.5B as of July 27, 2024.
What is the P/E ratio for InMode stock?
The price to earnings (P/E) ratio for InMode (INMD) stock is 8.34 as of July 27, 2024.
Does InMode stock pay dividends?
No, InMode (INMD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next InMode dividend payment date?
InMode (INMD) stock does not pay dividends to its shareholders.
What is the beta indicator for InMode?
InMode (INMD) has a beta rating of 2.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell InMode stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.